Efficacy of Annona glabra extract against acute hepatopancreatic necrosis disease in white-leg shrimp (Penaeus vannamei).

This study aims to investigate the use of pond apple (Annona glabra) compounds as a novel strategy to prevent and treat acute hepatopancreatic necrosis disease (AHPND) as well as to better understand the mechanism of health improvement in shrimp. The A. glabra leaf extracts were extracted using various solvents and examined for in vitro and in vivo activity against Vibrio parahaemolyticus strains. In comparison with ethanol and water extracts, methanol extract showed the strongest bactericidal effect (MBC/MIC ratio of 2.50 ± 1.00), with minimal inhibitory concentration (MIC) of 0.023 ± 0.012 mg ml-1 and minimum bactericidal concentration (MBC) of 0.065 ± 0.062 mg ml-1. White leg shrimp (P. vannamei, body weight 10.37 ± 0.27 g) fed A. glabra methanol extracts-containing diets (AMEDs) at 1 %, 1.5 %, and 2.0 % demonstrated no deleterious effects on survival and were significantly increased in length and weight after 30 days of feeding. The level of total haemocyte, hyaline haemocyte on day 15 and granulocyte on day 30 remarkably increased (p < 0.05) in shrimps fed AMEDs groups compared to those in the control group. The finding demonstrates that granulocyte was induced time dependently. In particular, the survival rate of V. parahaemolyticus challenged shrimps under medication with AMEDs at 1.5 % and 2.0 % was significantly higher (p < 0.05) than that of the control group. The decrease in bacterial load of Vibrio spp. and V. parahaemolyticus was obviously recorded in hepatopancreas shrimp given AMEDs 1.5 % and 2.0 % and may be linked to herb characteristics such as antibacterial activity, enhancing innate immunity, and its potential to maintain the integrity of hepatopancreatic tissue. Our findings suggest that A. glabra extract might be used as a health enhancer in commercial farmed shrimp.

Preliminary Result of Arthroscopic Anterior Cruciate Ligament Reconstruction Using Anterior Half of Peroneus Longus Tendon Autograft.

BACKGROUND: Arthroscopic anterior cruciate ligament reconstruction is one of the most successful operations in sports medicine. At present, ligament autografts have been the best method due to good histocompatibility, rapid healing, no cross-contamination, and low cost of treatment. However, autografts do not have infinite amount and are also not always feasible. Anterior half of peroneus longus tenden autograft is likely to become a source of autograft with many advantages. This study aims to evaluate the clinical outcomes of arthroscopic anterior cruciate ligament reconstruction using anterior half of peroneus longus tendon autograft (AHPLT). AIM: To evaluate the initial outcome of ACL reconstruction arthroscopy by anterior half of peroneus longus tendon. METHODS: This is a prospective non-controlled case series. RESULTS: A prospective study on 30 patients (from 9 / 2016 to 01 / 2019) had both ACL and MCL injury who had operated ACL reconstruction using anterior half of peroneus longus tendon autograft (AHPLT) at Department of General Orthopaedic and Trauma, Viet Duc hospital. Our outcome: the year average 35.4 ys, the rate of ACL rupture combined with meniscus injury was 40%. The average diameter AHPLT autograft is 7.0 mm. The function Lysholm scores improved from 59 to 94.27 postoperative 6 months. No difference beetwen the AOFAS scale of preoperative and postoperative. CONCLUSION: Peroneus longus tendon is recommended to be a safe and practical autograft resource for arthroscopic anterior cruciate ligament reconstruction.